Regeneron Pharmaceuticals (REGN) Common Equity (2009 - 2026)

Regeneron Pharmaceuticals' Common Equity history runs 18 years deep, the most recent figure standing at $31.4 billion for Q1 2026.

• In Q1 2026, Common Equity rose 6.93% year-over-year to $31.4 billion; the TTM figure through Mar 2026 stood at $31.4 billion (up 6.93% YoY), while the FY2025 annual figure was $31.3 billion, up 6.48% from the prior year.
• Common Equity was $31.4 billion for Q1 2026 at Regeneron Pharmaceuticals, up from $31.3 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $31.4 billion in Q1 2026 to a low of $19.9 billion in Q1 2022.
• Historically, Common Equity has averaged $26.5 billion across 5 years, with a median of $27.0 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Common Equity soared 66.27% in 2022, then gained 5.56% in 2025.
• A 5-year view of Common Equity shows it stood at $22.7 billion in 2022, then advanced by 14.6% to $26.0 billion in 2023, then grew by 13.02% to $29.4 billion in 2024, then grew by 6.48% to $31.3 billion in 2025, then grew by 0.53% to $31.4 billion in 2026.
• The last three Common Equity figures came in at $31.4 billion (Q1 2026), $31.3 billion (Q4 2025), and $31.0 billion (Q3 2025), per Business Quant data.